Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.6
Industry P/E
--
EV/EBITDA
2
Div. Yield
0 %
Debt to Equity
--
Book Value
$0.6
EPS
$-0.2
Face value
--
Shares outstanding
129,170,000
CFO
$-124.31 Mln
EBITDA
$-158.28 Mln
Net Profit
$-171.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
| 4.4 | 55.3 | 18.7 | -36.0 | 0.0 | -11.1 | -43.4 |
|
BSE Sensex*
| 5.1 | 7.1 | 8.3 | 12.7 | 15.9 | 21.5 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
| 7.2 | 66.5 | -66.9 | 68.4 | -39.5 | 53.9 | -67.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
|
1.0 | 133.1 | 0.0 | -25.5 | -153,450.0 | -31.4 | -- | 1.6 |
| 48.2 | 7,502.9 | 1,196.0 | 158.1 | 19.6 | 7.6 | 57.7 | 4.0 | |
| 99.5 | 6,297.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 18.4 | |
| 56.2 | 10,350.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 46.3 | 12,304.8 | 2,168.7 | 521.3 | 31.8 | 23.1 | 25.4 | 4.5 | |
| 49.0 | 8,204.1 | 1,084.3 | 485.4 | 43.3 | 103.8 | 17.7 | 16.8 | |
| 291.8 | 6,280.4 | 317.4 | -391.6 | -118.9 | -52.6 | -- | 8.8 | |
| 296.4 | 8,384.8 | 2,156.6 | 416.4 | 15.6 | 56.5 | 22.3 | 14.1 | |
| 23.7 | 9,289.5 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 120.3 | 11,755.2 | 2,412.6 | 305.8 | 20.5 | 11.6 | 40.3 | 4.6 |
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug... candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104 Read more
Chairman, CEO & President
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Chairman, CEO & President
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Atossa Genetics Inc (ATOS) stood at $ 76 Mln as on 31-Dec-24
The share price of Atossa Genetics Inc (ATOS) is $0.99 (NASDAQ) as of 15-May-2025 16:11 EDT. Atossa Genetics Inc (ATOS) has given a return of -0.02% in the last 3 years.
Atossa Genetics Inc (ATOS) has a market capitalisation of $ 133 Mln as on 15-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Atossa Genetics Inc (ATOS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Atossa Genetics Inc (ATOS) and enter the required number of quantities and click on buy to purchase the shares of Atossa Genetics Inc (ATOS).
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104
The CEO & director of Dr. Steven C. Quay FCAP, M.D., Ph.D.. is Atossa Genetics Inc (ATOS), and CFO & Sr. VP is Dr. Steven C. Quay FCAP, M.D., Ph.D..
There is no promoter pledging in Atossa Genetics Inc (ATOS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,098
|
|
|
1,086
|
|
|
1,077
|
|
|
1,006
|
|
|
864
|
|
|
787
|
|
|
756
|
|
|
680
|
|
|
658
|
| Atossa Genetics Inc (ATOS) | Ratios |
|---|---|
|
Return on equity(%)
|
-31.39
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Atossa Genetics Inc (ATOS) was $0 Mln.
$-0.04
(
